Literature DB >> 17145699

Evaluation of which reactive metabolite, if any, is responsible for a specific idiosyncratic reaction.

Jack Uetrecht1.   

Abstract

Reactive metabolites are believed to be responsible for most idiosyncratic drug reactions. It is often assumed that if a reactive metabolite is found, it must be responsible for the idiosyncratic reactions associated with that drug. However, the evidence linking reactive metabolites and idiosyncratic reactions is circumstantial at best, and in many cases we have virtually no evidence. Furthermore, it is common for a drug to form several reactive metabolites, so it can be difficult to determine which, if any, is responsible for a given idiosyncratic reaction. Although the reactive metabolite hypothesis is logical, it has important implications for drug development, and we need to develop ways to test the hypothesis for specific drugs rigorously. Valid animal models are a powerful tool for testing whether a specific reactive metabolite is responsible for a specific adverse reaction and for studying further the mechanism by which it may induce such reactions; however, such models are rare.

Mesh:

Substances:

Year:  2006        PMID: 17145699     DOI: 10.1080/03602530600959615

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  7 in total

Review 1.  Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity.

Authors:  Patrick J Shaw; Patricia E Ganey; Robert A Roth
Journal:  Toxicol Sci       Date:  2010-06-10       Impact factor: 4.849

2.  Strategies for discovering and derisking covalent, irreversible enzyme inhibitors.

Authors:  Douglas S Johnson; Eranthie Weerapana; Benjamin F Cravatt
Journal:  Future Med Chem       Date:  2010-06       Impact factor: 3.808

Review 3.  Role of biotransformation studies in minimizing metabolism-related liabilities in drug discovery.

Authors:  Yue-Zhong Shu; Benjamin M Johnson; Tian J Yang
Journal:  AAPS J       Date:  2008-03-13       Impact factor: 4.009

4.  [Delayed-type cutaneous drug reactions. Pathogenesis, clinical features and histology].

Authors:  M Ziemer
Journal:  Hautarzt       Date:  2014-05       Impact factor: 0.751

Review 5.  "Autoimmune(-Like)" Drug and Herb Induced Liver Injury: New Insights into Molecular Pathogenesis.

Authors:  Marcial Sebode; Lisa Schulz; Ansgar W Lohse
Journal:  Int J Mol Sci       Date:  2017-09-12       Impact factor: 5.923

Review 6.  Models of Drug Induced Liver Injury (DILI) - Current Issues and Future Perspectives.

Authors:  Lucija Kuna; Ivana Bozic; Tomislav Kizivat; Kristina Bojanic; Margareta Mrso; Edgar Kralj; Robert Smolic; George Y Wu; Martina Smolic
Journal:  Curr Drug Metab       Date:  2018       Impact factor: 3.731

7.  Covalent Histone Modification by an Electrophilic Derivative of the Anti-HIV Drug Nevirapine.

Authors:  Shrika G Harjivan; Catarina Charneira; Inês L Martins; Sofia A Pereira; Guadalupe Espadas; Eduard Sabidó; Frederick A Beland; M Matilde Marques; Alexandra M M Antunes
Journal:  Molecules       Date:  2021-03-03       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.